Immunomedics (IMMU) Reports In-Line Q4 Loss of 13c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts IMMU Hot Sheet
Price: $87.86 --0%
Financial Fact:
Less net (loss) attributable to noncontrolling interest: -31.05K
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
Less net (loss) attributable to noncontrolling interest: -31.05K
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Immunomedics (NASDAQ: IMMU) reported Q4 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $1.13 million.
For earnings history and earnings-related data on Immunomedics (IMMU) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Core Molding Technologies, Inc. (CMT) Misses Q3 EPS by 3c
- Moody’s lifts Nokia to Baa3 investment grade on AI and cloud momentum
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
